单位(元)汇添富创新医药混合(006113)利润表 |
报告期 |
2023/12/31 |
2023/6/30 |
2022/12/31 |
2022/6/30 |
收入 |
-1,561,319,504 |
-942,773,621 |
-2,525,482,995 |
-1,210,380,236 |
利息收入 |
3,391,004 |
2,185,435 |
7,970,068 |
2,783,610 |
其中:存款利息收入 |
3,391,004 |
2,185,435 |
7,970,068 |
2,783,610 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益 |
-1,300,011,715 |
-668,172,895 |
-1,446,210,124 |
-661,019,364 |
其中:股票投资收益 |
-1,371,563,077 |
-722,716,843 |
-1,498,568,432 |
-701,539,549 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
8,225,875 |
2,119,392 |
7,418,810 |
8,183,869 |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
63,325,487 |
52,424,556 |
44,939,497 |
32,336,315 |
公允价值变动收益 |
-266,539,823 |
-278,227,131 |
-1,091,664,047 |
-554,804,994 |
汇兑收益 |
- |
- |
- |
- |
其他收入 |
1,841,030 |
1,440,970 |
4,421,108 |
2,660,513 |
费用 |
125,868,563 |
74,812,437 |
158,067,319 |
79,227,376 |
管理人报酬 |
107,661,764 |
64,014,881 |
135,263,720 |
67,799,160 |
托管费 |
17,943,627 |
10,669,147 |
22,543,953 |
11,299,860 |
销售服务费 |
- |
- |
- |
- |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
263,172 |
128,409 |
259,645 |
128,355 |
利润总额 |
-1,687,188,067 |
-1,017,586,058 |
-2,683,550,314 |
-1,289,607,611 |
减:所得税费用 |
- |
- |
- |
- |
净利润 |
-1,687,188,067 |
-1,017,586,058 |
-2,683,550,314 |
-1,289,607,611 |
*注:新浪财经提醒:以上数据由合作伙伴提供,仅供参考,交易请以正式公告数据为准。